Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare News Papua New Guinea.
Press releases published on September 3, 2025
Molecular Assay Market to Grow at a CAGR of 7% During the Forecast Period (2025 – 2030): Wissen Research
GlobeNewswire
·
September 3, 2025
Sheridan, Sept. 03, 2025 (GLOBE NEWSWIRE) -- According to the latest market report published by Wissen Research, the global molecular assay market was valued at USD 16.4 billion in 2024. Furthermore, the market is expected to grow at a CAGR of 7% during …
UPDATE -- vTv Therapeutics to Participate in Upcoming September Investor Conferences
GlobeNewswire
·
September 3, 2025
HIGH POINT, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being …
Sotera Health Announces Secondary Offering of Common Stock
GlobeNewswire
·
September 3, 2025
CLEVELAND, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC) (the “Company”) today announced the launch of a secondary offering (the “Offering”) of 20,000,000 shares of its common stock, par value $0.01 per share. All 20,000,000 shares …
Artelo Biosciences Announces Proposed Underwritten Public Offering
GlobeNewswire
·
September 3, 2025
SOLANA BEACH, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic …
DBV Technologies to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire
·
September 3, 2025
Châtillon, France, September 3, 2025 DBV Technologies to Participate in the H.C. Wainwright 27th Annual Global Investment Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage …
DBV Technologies participera à la 27e conférence annuelle H.C. Wainwright Global Investment
GlobeNewswire
·
September 3, 2025
Châtillon, France, le 3 septembre (22:30 CEST) 2025 DBV Technologies participera à la 27e conférence annuelle H.C. Wainwright Global Investment DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP : 23306J309), une …
Pennant Announces Home Health Acquisition in Wyoming
GlobeNewswire
·
September 3, 2025
EAGLE, Idaho, Sept. 03, 2025 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice, home care and senior living companies, announced today that effective September 1, 2025, it …
Avadel Pharmaceuticals Strengthens Sleep Medicine Portfolio with Exclusive License of Valiloxybate from XWPharma Ltd
GlobeNewswire
·
September 3, 2025
– Expands Avadel’s pipeline with salt-free, artificial sweetener-free, once-at-bedtime oxybate for treatment of narcolepsy and idiopathic hypersomnia – – Initial pharmacokinetic (PK) and comparative bioavailability study to initiate in fourth quarter 2025 …
Surrozen to Present at Upcoming Healthcare Investor Conference
GlobeNewswire
·
September 3, 2025
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway, with a focus on severe eye …
Resmed Launches Sleep Institute to Elevate Sleep Health as a Global Priority
GlobeNewswire
·
September 3, 2025
SAN DIEGO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced the launch of Sleep Institute, a global clinical insights …
Aligos Therapeutics Announces Six Preclinical Presentations at the 2025 International HBV Meeting
GlobeNewswire
·
September 3, 2025
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today …
Longeveron® Announces Key Leadership Updates
GlobeNewswire
·
September 3, 2025
Than Powell, Chief Business Officer and head of business development, appointed Interim CEO Dr. Joshua Hare, co-founder and chief science officer, appointed Executive Chairman of the Board of Directors Wa’el Hashad to step down as CEO and Board member …
SAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of Diabetes
GlobeNewswire
·
September 3, 2025
MIAMI, Sept. 03, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing a multi-specific human anti-thymocyte …
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
September 3, 2025
SAN DIEGO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to …
American Botanical Council Debuts Saw Palmetto Educational Video on HerbTV
GlobeNewswire
·
September 3, 2025
Austin, Texas, Sept. 03, 2025 (GLOBE NEWSWIRE) -- The nonprofit American Botanical Council (ABC) announces the premiere of its new educational video, “Saw Palmetto: Safe and Effective Herb for Prostate and Men’s Urinary Health.” The video is available on …
Clover Health CEO Andrew Toy Testifies Before Congress on the Transformative Role of AI in Healthcare, Highlights how Clover is Leading the Way
GlobeNewswire
·
September 3, 2025
WASHINGTON, D.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”) – Clover Health CEO Andrew Toy today had the honor to deliver testimony before the U.S. House of …
New Study: Gut Health Program Cuts Infant Eczema Odds by 83% in C-Section Babies
GlobeNewswire
·
September 3, 2025
AUSTIN, Texas, Sept. 03, 2025 (GLOBE NEWSWIRE) -- A new study found that babies born by C-section had 83% lower odds of developing eczema when their families participated in a 6-month gut health support program, compared to those who didn't receive the …
PharmaCorp to Acquire Two Pharmacies in Western Canada
GlobeNewswire
·
September 3, 2025
SASKATOON, Saskatchewan, Sept. 03, 2025 (GLOBE NEWSWIRE) -- PHARMACORP RX INC. (“PharmaCorp” or the “Corporation”) (TSXV: PCRX) is pleased to announce that it has entered into definitive share purchase agreements, each dated August 29, 2025 (the “ …
Microbix Hosts Ontario Minister Stephen Crawford
GlobeNewswire
·
September 3, 2025
MISSISSAUGA, Ontario, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces its hosting of the Honourable Stephen Crawford, Ontario’s Minister of …
Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients
GlobeNewswire
·
September 3, 2025
First-ever potentially disease-modifying therapy for uncontrolled Graves’ disease patients Of 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response, resulting in normal thyroid function (T3 and T4 less …